| Missing Links?: 6 Citation Matrix | Graphs | Glossary HistCite Guide About |
|
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
Sordella R, Bell DW, Haber DA, Settleman J SCIENCE 305 (5687): 1163-1167 AUG 20 2004 and the citing papers |
Nodes: 133,
Authors: 644,
Journals: 70,
Outer References: 5674,
Words: 517
Collection span: 2004 - 2006
View: Overview. Sorted by year, source, volume, issue, page.
Page 1 of 2: [ 1 2 ]
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
|---|---|---|---|---|---|
| 1 | 1 | 15 | 1 2004 CANCER RESEARCH 64 (24): 9101-9104 Arao T; Fukumoto H; Takeda M; Tamura T; Saijo N; et al. Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474 | 5 | 10 |
| 2 | 1 | 8 | 2 2004 CELL CYCLE 3 (12): 1496-1497 Settleman J Inhibition of mutant EGF receptors by Gefitinib - Targeting an Achilles' heel of lung cancer | 3 | 4 |
| 3 | 1 | 88 | 3 2004 DRUGS 64 (21): 2475-2492 Frampton JE; Easthope SE Gefitinib - A review of its use in the management of advanced non-small-cell lung cancer | 0 | 5 |
| 4 | 1 | 69 | 4 2004 DRUGS OF TODAY 40 (10): 809-827 Tanovic A; Alfaro V Current status in the treatment of non-small cell lung cancer | 0 | 2 |
| 5 | 1 | 34 | 5 2004 HUMAN MOLECULAR GENETICS 13 (24): 3029-3043 Kakiuchi S; Daigo Y; Ishikawa N; Furukawa C; Tsunoda T; et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839) | 1 | 5 |
| 6 | 1 | 31 | 6 2004 NATURE 432 (7015): 294-297 Sawyers C Targeted cancer therapy | 3 | 18 |
| 7 | 1 | 88 | 7 2004 NATURE REVIEWS CANCER 4 (12): 956-965 Herbst RS; Fukuoka M; Baselga J Timeline - Gefitinib - a novel targeted approach to treating cancer | 6 | 18 |
| 8 | 1 | 92 | 8 2004 NATURE REVIEWS DRUG DISCOVERY 3 (12): 1001-1010 Daub H; Specht K; Ullrich A Strategies to overcome resistance to targeted protein kinase inhibitors | 2 | 24 |
| 9 | 1 | 62 | 9 2004 ONCOGENE 23 (51): 8392-8400 Willingham AT; Deveraux QL; Hampton GM; Aza-Blanc P RNAi and HTS: exploring cancer by systematic loss-of-function | 1 | 5 |
| 10 | 0 | 19 | 10 2004 SCIENCE 305 (5687): 1163-1167 Sordella R; Bell DW; Haber DA; Settleman J Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways | 132 | 132 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 11 | 1 | 34 | 11 2004 TRENDS IN MOLECULAR MEDICINE 10 (10): 481-486 Gazdar AF; Shigematsu H; Herz J; Minna JD Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? | 11 | 20 |
| 12 | 1 | 125 | 12 2005 AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY 13 (12): 1027-1040 Gershenfeld HK; Philibert RA; Boehm GW Looking forward in geriatric anxiety and depression - Implications of basic science for the future | 0 | 1 |
| 13 | 1 | 34 | 13 2005 AMERICAN JOURNAL OF PHARMACOGENOMICS 5 (2): 133-136 Frampton JE; Easthope SE Spotlight on gefitinib in non-small-cell lung cancer | 0 | 0 |
| 14 | 1 | 31 | 14 2005 AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY 289 (2): C257-C263 Guo TB; Lu JW; Li T; Lu ZY; Xu GT; et al. Insulin-activated, K+-channel-sensitive Akt pathway is primary mediator of ML-1 cell proliferation | 0 | 0 |
| 15 | 1 | 50 | 15 2005 AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY 33 (5): 490-499 Sithanandam G; Smith GT; Fields JR; Fornwald LW; Anderson LM Alternate paths from epidermal growth factor receptor to Akt in malignant versus nontransformed lung epithelial cells - ErbB3 versus Gab1 | 0 | 0 |
| 16 | 1 | 57 | 16 2005 AMERICAN JOURNAL OF SURGICAL PATHOLOGY 29 (5): 633-639 Yatabe Y; Kosaka T; Takahashi T; Mitsudomi T EGFR mutation is specific for terminal respiratory unit type adenocarcinoma | 1 | 1 |
| 17 | 2 | 21 | 17 2005 ANNALS OF ONCOLOGY 16 (7): 1081-1086 Cortes-Funes H; Gomez C; Rosell R; Valero P; Garcia-Giron C; et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients | 1 | 3 |
| 18 | 1 | 40 | 18 2005 BIOORGANIC & MEDICINAL CHEMISTRY 13 (8): 2825-2836 Alaimo PJ; Knight ZA; Shokat KM Targeting the gatekeeper residue in phosphoinositide 3-kinases | 1 | 1 |
| 19 | 1 | 35 | 19 2005 BRITISH JOURNAL OF CANCER 92 (9): 1690-1695 Ueno Y; Sakurai H; Matsuo M; Choo MK; Koizumi K; et al. Selective inhibition of TNF-alpha-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib | 0 | 0 |
| 20 | 4 | 38 | 20 2005 BRITISH JOURNAL OF CANCER 93 (12): 1334-1340 Cappuzzo F; Toschi L; Domenichini I; Bartolini S; Ceresoli GL; et al. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients | 0 | 0 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 21 | 1 | 41 | 21 2005 CANCER CELL 8 (3): 227-239 Schardt JA; Meyer M; Hartmann CH; Schubert F; Schmidt-Kittler O; et al. Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer | 0 | 0 |
| 22 | 1 | 155 | 22 2005 CANCER LETTERS 227 (1): 9-23 Rabindran SK Antitumor activity of HER-2 inhibitors | 0 | 0 |
| 23 | 1 | 50 | 23 2005 CANCER RESEARCH 65 (1): 46-53 Liu WQ; Innocenti F; Wu MH; Desai AA; Dolan ME; et al. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter | 1 | 3 |
| 24 | 1 | 73 | 24 2005 CANCER RESEARCH 65 (1): 338-348 Lo HW; Xia WY; Wei YK; Ali-Seyed M; Huang SF; et al. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer | 0 | 7 |
| 25 | 1 | 20 | 25 2005 CANCER RESEARCH 65 (8): 3003-3010 Jimeno A; Rubio-Viqueira B; Amador ML; Oppenheimer D; Bouraoud N; et al. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents | 1 | 1 |
| 26 | 1 | 60 | 26 2005 CANCER RESEARCH 65 (8): 3226-3235 Wislez M; Spencer ML; Izzo JG; Juroske DM; Balhara K; et al. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras | 0 | 4 |
| 27 | 3 | 55 | 27 2005 CANCER RESEARCH 65 (14): 6401-6408 Shimamura T; Lowell AM; Engelman JA; Shapiro GI Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins | 0 | 0 |
| 28 | 3 | 20 | 28 2005 CANCER RESEARCH 65 (16): 7096-7101 Kobayashi S; Ji HB; Yuza Y; Meyerson M; Wong KK; et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor | 0 | 0 |
| 29 | 2 | 26 | 29 2005 CANCER RESEARCH 65 (16): 7276-7282 Nagai Y; Miyazawa H; Huqun; Tanaka T; Udagawa K; et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp | 0 | 0 |
| 30 | 10 | 27 | 30 2005 CANCER RESEARCH 65 (17): 7525-7529 Johnson BE; Janne PA Epidermal growth factor receptor mutations in patients with non-small cell lung cancer | 0 | 1 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 31 | 3 | 19 | 31 2005 CANCER RESEARCH 65 (17): 7568-7572 Tang XN; Shigematsu H; Bekele BN; Roth JA; Minna JD; et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients | 0 | 0 |
| 32 | 3 | 38 | 32 2005 CANCER RESEARCH 65 (19): 8968-8974 Jiang JR; Greulich H; Janne PA; Sellers WR; Meyerson M; et al. Epidermal growth factor independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression | 0 | 0 |
| 33 | 1 | 55 | 33 2005 CANCER SCIENCE 96 (2): 63-68 Tomida S; Yatabe Y; Yanagisawa K; Mitsudomi T; Takahashi T Throwing new light on lung cancer pathogenesis: Updates on three recent topics | 0 | 2 |
| 34 | 4 | 163 | 34 2005 CELL CYCLE 4 (2): 269-278 Blagosklonny MV How cancer could be cured by 2015 | 1 | 1 |
| 35 | 1 | 24 | 35 2005 CELL CYCLE 4 (4): 518-520 Graveel CR; London CA; Vande Woude GF A mouse model of activating met mutations | 0 | 1 |
| 36 | 1 | 63 | 36 2005 CELL CYCLE 4 (4): 578-581 Kang S; Bader AG; Zhao L; Vogt PK Mutated PI 3-kinases - Cancer targets on a silver platter | 0 | 1 |
| 37 | 1 | 46 | 37 2005 CELL CYCLE 4 (5): 683-685 Wickramasinghe D; Kong-Beltran M Met activation and receptor dimerization in cancer - A role for the Sema domain | 0 | 0 |
| 38 | 7 | 43 | 38 2005 CELL CYCLE 4 (10): 1369-1372 Haas-Koogan DA; Prados MD; Lamborn KR; Tihan T; Berger MS; et al. Biomarkers to predict response to epidermal growth factor receptor inhibitors | 0 | 0 |
| 39 | 2 | 152 | 39 2005 CELL DEATH AND DIFFERENTIATION 12 (6): 592-602 Blagosklonny MV Carcinogenesis, cancer therapy and chemoprevention | 0 | 3 |
| 40 | 1 | 7 | 40 2005 CHEST 127 (6): 2292-2292 Altundag O; Altundag K; Morandi P; Gunduz M Association between epidermal growth factor receptor mutation and improved survival in never-smokers with primary adenocarcinoma of the lung | 0 | 0 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 41 | 1 | 55 | 41 2005 CHEST 128 (1): 308-316 Zheng Z; Bepler G; Cantor A; Haura EB Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer | 1 | 1 |
| 42 | 1 | 140 | 42 2005 CLINICAL CANCER RESEARCH 11 (1): 129-138 Lin MZ; Teitell MA; Schiller GJ The evolution of antibodies into versatile tumor-targeting | 0 | 2 |
| 43 | 1 | 29 | 43 2005 CLINICAL CANCER RESEARCH 11 (6): 2244-2251 Kim KS; Jeong JY; Kim YC; Na KJ; Kim YH; et al. Predictors of the response to gefitinib in refractory non-small cell lung cancer | 3 | 3 |
| 44 | 1 | 15 | 44 2005 CLINICAL CANCER RESEARCH 11 (8): 2879-2882 Lee JW; Soung YH; Kim SY; Nam HK; Park WS; et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck | 4 | 8 |
| 45 | 1 | 63 | 45 2005 CLINICAL CANCER RESEARCH 11 (10): 3668-3677 Tarn C; Merkel E; Canutescu AA; Shen W; Skorobogatko Y; et al. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: Therapeutic implications through protein modeling | 0 | 2 |
| 46 | 5 | 29 | 46 2005 CLINICAL CANCER RESEARCH 11 (16): 5668-5670 Sequist LV; Haber DA; Lynch TJ Epidermal growth factor receptor mutations in non-small cell lung cancer: Predicting clinical response to kinase inhibitors | 1 | 1 |
| 47 | 3 | 35 | 47 2005 CLINICAL CANCER RESEARCH 11 (16): 5878-5885 Taron M; Ichinose Y; Rosell R; Mok T; Massuti B; et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas | 2 | 3 |
| 48 | 2 | 49 | 48 2005 CLINICAL CANCER RESEARCH 11 (17): 6177-6185 Shibata T; Uryu S; Kokubu A; Hosoda F; Ohki M; et al. Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: Its association with clinicopathologic features | 0 | 0 |
| 49 | 1 | 38 | 49 2005 CLINICAL CANCER RESEARCH 11 (18): 6650-6656 Ogino S; Meyerhardt JA; Cantor M; Brahmandam M; Clark JW; et al. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer | 0 | 0 |
| 50 | 1 | 39 | 50 2005 CLINICAL CANCER RESEARCH 11 (21): 7841-7850 Lassman AB; Rossi MR; Razier JR; Abrey LE; Lieberman FS; et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: Tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01 | 0 | 0 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 51 | 3 | 27 | 51 2005 CLINICAL CANCER RESEARCH 11 (22): 8105-8108 Cohen EEW; Lingen MW; Martin LE; Harris PL; Brannigan BW; et al. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR | 0 | 0 |
| 52 | 8 | 38 | 52 2005 CLINICAL CANCER RESEARCH 11 (23): 8288-8294 Haura EB; Zheng Z; Song LX; Cantor A; Bepler G Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer | 0 | 0 |
| 53 | 1 | 133 | 53 2005 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 55 (2): 103-116 Cengel KA; McKenna WG Molecular targets for altering radiosensitivity: Lessons from Ras as a pre-clinical and clinical model | 0 | 0 |
| 54 | 1 | 88 | 54 2005 CURRENT MEDICINAL CHEMISTRY 12 (15): 1773-1781 Carlomagno F; Santoro M Receptor tyrosine kinases as targets for anticancer therapeutics | 0 | 0 |
| 55 | 2 | 30 | 55 2005 CURRENT OPINION IN ONCOLOGY 17 (2): 118-122 Hirsch FR; Witta S Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer | 1 | 2 |
| 56 | 1 | 39 | 56 2005 CURRENT OPINION IN ONCOLOGY 17 (2): 123-129 Perrone F; Di Maio M; Budillon A; Normanno N Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trials | 0 | 1 |
| 57 | 5 | 51 | 57 2005 CURRENT OPINION IN PHARMACOLOGY 5 (4): 343-349 Speake G; Holloway B; Costello G Recent developments related to the EGFR as a target for cancer chemotherapy | 0 | 1 |
| 58 | 1 | 111 | 58 2005 CURRENT SCIENCE 88 (6): 890-898 Nair P Epidermal growth factor receptor family and its role in cancer progression | 0 | 0 |
| 59 | 1 | 107 | 59 2005 CURRENT TOPICS IN MEDICINAL CHEMISTRY 5 (2): 109-125 Barnett SF; Bilodeau MT; Lindsley CW The Akt/PKB family of protein kinases: A review of small molecule inhibitors and progress towards target validation | 1 | 3 |
| 60 | 2 | 128 | 60 2005 DRUG RESISTANCE UPDATES 8 (5): 298-310 Morgillo F; Lee HY Resistance to epidermal growth factor receptor-targeted therapy | 0 | 0 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 61 | 1 | 17 | 61 2005 EUROPEAN JOURNAL OF CANCER 41 (9): 1286-1290 Okamoto T; Nakamura T; Ikeda J; Maruyama R; Shoji F; et al. Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer | 0 | 0 |
| 62 | 2 | 52 | 62 2005 EXPERT OPINION ON PHARMACOTHERAPY 6 (6): 985-993 Tamura K; Fukuoka M Gefitinib in non-small cell lung cancer | 0 | 3 |
| 63 | 5 | 243 | 63 2005 EXPERT OPINION ON THERAPEUTIC TARGETS 9 (4): 769-790 Rogers SJ; Box C; Harrington KJ; Nutting C; Rhys-Evans P; et al. The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck | 0 | 0 |
| 64 | 1 | 50 | 64 2005 EXPERT OPINION ON THERAPEUTIC TARGETS 9 (4): 851-860 Stern DF Phosphoproteomics for oncology discovery and treatment | 0 | 0 |
| 65 | 2 | 151 | 65 2005 EXPERT OPINION ON THERAPEUTIC TARGETS 9 (5): 1009-1030 Shelton JG; Steelman LS; Abrams SL; Bertrand FE; Franklin RA; et al. The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it? | 0 | 1 |
| 66 | 1 | 183 | 66 2005 EXPERT OPINION ON THERAPEUTIC TARGETS 9 (6): 1147-1163 Paz K; Zhu ZP Recent advances in targeted therapy of human myelogenous leukaemia | 0 | 0 |
| 67 | 3 | 55 | 67 2005 EXPERT REVIEW OF ANTICANCER THERAPY 5 (4): 727-735 Jimeno A; Hidalgo M Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity | 0 | 0 |
| 68 | 1 | 146 | 68 2005 HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA 19 (2): 343-+ Hahn O; Salgia R Novel therapies in lung cancer | 0 | 0 |
| 69 | 1 | 145 | 69 2005 HISTOLOGY AND HISTOPATHOLOGY 20 (1): 299-315 Chong ZZ; Li F; Maiese K Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury | 1 | 8 |
| 70 | 1 | 37 | 70 2005 HUMAN PATHOLOGY 36 (5): 486-493 Willmore-Payne C; Holden JA; Tripp S; Layfield LJ Human malignant melanoma: detection of BRAF-and c-kit-activating mutations by high-resolution amplicon melting analysis | 0 | 0 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 71 | 4 | 38 | 71 2005 HUMAN PATHOLOGY 36 (10): 1127-1134 Suzuki M; Shigematsu H; Hiroshima K; Iizasa T; Nakatani Y; et al. Epidermal growth factor receptor expression status in lung cancer correlates with its mutation | 0 | 0 |
| 72 | 1 | 48 | 72 2005 INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 15: 42-50 Du Bois A; Pfisterer J Future options for first-line therapy of advanced ovarian cancer | 0 | 0 |
| 73 | 1 | 9 | 73 2005 INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 62 (4): 1253-1253 Altundag K; Altundag O; Gunduz E; Boruban C Activation patterns of epidermal growth factor-receptor signaling in glioblastoma multiforme: In regard to Chakravarti et al. (Int J Radiat Oncol Biol Phys 2005;62 : 318-327) | 0 | 0 |
| 74 | 1 | 44 | 74 2005 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 46 (6): 2035-2041 Zhang X; Neufeld AH Activation of the epidermal growth factor receptor in optic nerve astrocytes leads to early and transient induction of cyclooxygenase-2 | 0 | 0 |
| 75 | 1 | 36 | 75 2005 JAPANESE JOURNAL OF CLINICAL ONCOLOGY 35 (5): 233-238 Yoshimoto A; Kasahara K; Nishio M; Hourai T; Sone T; et al. Changes in angiogenic growth factor levels after gefitinib treatment in non-small cell lung cancer | 0 | 0 |
| 76 | 1 | 62 | 76 2005 JOURNAL OF BIOLOGICAL CHEMISTRY 280 (35): 31101-31108 Basso AD; Mirza A; Liu GJ; Long BJ; Bishop WR; et al. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling - Role in FTI enhancement of taxane and tamoxifen anti-tumor activity | 0 | 0 |
| 77 | 1 | 73 | 77 2005 JOURNAL OF BIOLOGICAL CHEMISTRY 280 (45): 37383-37392 Liu ZP; Li HB; Derouet M; Filmus J; LaCasse EC; et al. ras oncogene triggers up-regulation of cIAP2 and XIAP in intestinal epithelial cells - Epidermal growth factor receptor-dependent and -independent mechanisms of ras-induced transformation | 0 | 0 |
| 78 | 2 | 75 | 78 2005 JOURNAL OF CELLULAR PHYSIOLOGY 205 (3): 355-363 Di Maio M; Gridelli C; Normanno N; Perrone F; Ciardiello F Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer | 0 | 0 |
| 79 | 1 | 84 | 79 2005 JOURNAL OF CLINICAL INVESTIGATION 115 (10): 2618-2624 Amaravadi R; Thompson CB The survival kinases Akt and Pim as potential pharmacological targets | 0 | 1 |
| 80 | 1 | 34 | 80 2005 JOURNAL OF CLINICAL ONCOLOGY 23 (9): 1791-1793 Meropol NJ Epidermal growth factor receptor inhibitors in colorectal cancer: It's time to get back on target | 0 | 2 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 81 | 3 | 133 | 81 2005 JOURNAL OF CLINICAL ONCOLOGY 23 (11): 2445-2459 Baselga J; Arteaga CL Critical update and emerging trends in epidermal growth factor receptor targeting in cancer | 1 | 11 |
| 82 | 1 | 21 | 82 2005 JOURNAL OF CLINICAL ONCOLOGY 23 (11): 2493-2501 Han SW; Kim TY; Hwang PG; Jeong S; Kim J; et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib | 8 | 24 |
| 83 | 1 | 26 | 83 2005 JOURNAL OF CLINICAL ONCOLOGY 23 (11): 2513-2520 Mitsudomi T; Kosaka T; Endoh H; Horio Y; Hida T; et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence | 8 | 18 |
| 84 | 2 | 102 | 84 2005 JOURNAL OF CLINICAL ONCOLOGY 23 (11): 2556-2568 Pao W; Miller VA Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions | 5 | 24 |
| 85 | 2 | 53 | 85 2005 JOURNAL OF CLINICAL ONCOLOGY 23 (14): 3227-3234 Janne PA; Engelman JA; Johnson BE Epidermal growth factor receptor mutations in non-small-cell lung cancer: Implications for treatment and tumor biology | 2 | 8 |
| 86 | 3 | 47 | 86 2005 JOURNAL OF CLINICAL ONCOLOGY 23 (22): 5007-5018 Cappuzzo F; Varella-Garcia M; Shigematsu H; Domenichini I; Bartolini S; et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients | 2 | 5 |
| 87 | 1 | 126 | 87 2005 JOURNAL OF CLINICAL ONCOLOGY 23 (26): 6306-6315 Armstrong SA; Look AT Molecular genetics of acute lymphoblastic leukemia | 0 | 0 |
| 88 | 7 | 39 | 88 2005 JOURNAL OF CLINICAL ONCOLOGY 23 (31): 8081-8092 Bell DW; Lynch TJ; Haserlat SM; Harris PL; Okimoto RA; et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials | 0 | 1 |
| 89 | 1 | 40 | 89 2005 JOURNAL OF CLINICAL ONCOLOGY 23 (36): 9105-9112 Ramirez JL; Rosell R; Taron M; Sanchez-Ronco M; Alberola V; et al. 14-3-3 sigma Methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group | 0 | 0 |
| 90 | 1 | 79 | 90 2005 JOURNAL OF GENERAL PHYSIOLOGY 126 (1): 41-53 McLaughlin S; Smith SO; Hayman MJ; Murray D An electrostatic engine model for autoinhibition and activation of the epidermal growth factor receptor (EGFR/ErbB) family | 0 | 1 |
| # | LCR | NCR | Node / Date / Journal / Author | LCS | GCS |
| 91 | 2 | 16 | 91 2005 JOURNAL OF MOLECULAR DIAGNOSTICS 7 (3): 396-403 Pan QL; Pao W; Ladanyi M Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas | 0 | 0 |
| 92 | 2 | 38 | 92 2005 JOURNAL OF THE NATIONAL CANCER INSTITUTE 97 (5): 339-346 Shigematsu H; Lin L; Takahashi T; Nomura M; Suzuki M; et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers | 13 | 44 |
| 93 | 1 | 7 | 93 2005 JOURNAL OF THE NATIONAL CANCER INSTITUTE 97 (6): 462-463 Cappuzzo F Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer - Reply | 0 | 0 |
| 94 | 1 | 41 | 94 2005 JOURNAL OF THE NATIONAL CANCER INSTITUTE 97 (9): 643-655 Cappuzzo F; Hirsch FR; Rossi E; Bartolini S; Ceresoli GL; et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer | 14 | 33 |
| 95 | 2 | 22 | 95 2005 JOURNAL OF THE NATIONAL CANCER INSTITUTE 97 (12): 868-869 Cappuzzo F Erlotinib in gliomas: Should selection be based on EGFR and Akt analyses? | 0 | 1 |
| 96 | 2 | 35 | 96 2005 LUNG CANCER 50 (1): 1-8 Yoshida Y; Shibata T; Kokubu A; Tsuta K; Matsuno Y; et al. Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung | 0 | 0 |
| 97 | 1 | 24 | 97 2005 LUNG CANCER 50 (1): 25-33 Rosell R; Ichinose Y; Taron M; Sarries C; Queralt C; et al. Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer | 0 | 0 |
| 98 | 3 | 25 | 98 2005 LUNG CANCER 50 (3): 375-384 Endo K; Konishi A; Sasaki H; Takada M; Tanaka H; et al. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay | 0 | 0 |
| 99 | 13 | 57 | 99 2005 NATURE CLINICAL PRACTICE ONCOLOGY 2 (11): 554-561 Giaccone G; Rodriguez JA EGFR inhibitors: what have we learned from the treatment of lung cancer? | 0 | 0 |
| 100 | 5 | 15 | 100 2005 NATURE GENETICS 37 (12): 1315-1316 Bell DW; Gore I; Okimoto RA; Godin-Heymann N; Sordella R; et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR | 0 | 0 |
Page 1 of 2: [ 1 2 ]
Generated by: HistCite 2005.08.29